The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
Open accessAbstract
Objective: To continue evaluation of the long‐term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD). Three‐year progression of eteplirsen‐treated patients was compared to matched historical controls (HC). Methods: Ambulatory DMD patients who were ≥7 years old and amenable to exon 51 skipping were randomized to eteplirsen (30/50mg/kg) or placebo for 24 weeks. Thereafter, all received eteplirsen on an open‐label basis. The primary functional assessment in this study was the 6‐Minute Walk Test (6MWT). Respiratory muscle function was assessed by pulmonary function testing (PFT). Longitudinal natural history data were used for comparative analysis of 6MWT performance at baseline and months 12, 24, and 36. Patients were matched to the eteplirsen group based on age, corticosteroid use, and genotype. Results: At 36 months, eteplirsen‐treated patients (n = 12) demonstrated a statistically significant advantage of 151m ( p < 0.01) on 6MWT and experienced a lower incidence of loss of ambulation in comparison to matched HC (n = 13) amenable to exon 51 skipping. PFT results remained relatively stable in eteplirsen‐treated patients. Eteplirsen was well tolerated. Analysis of HC confirmed the previously observed change in disease trajectory at age 7 years, and more severe progression was observed in patients with mutations amenable to exon skipping than in those not amenable. The subset of patients amenable to exon 51 skipping showed a more severe disease course than those amenable to any exon skipping. Interpretation: Over 3 years of follow‐up, eteplirsen‐treated patients showed a slower rate of decline in ambulation assessed by 6MWT compared to untreated matched HC. Ann Neurol 2016;79:257–271
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Prevalence of Muscular Dystrophies: A Systematic Literature Review
Theadom, A., Rodrigues, M., Roxburgh, R., Balalla, S., Higgins, C., Bhattacharjee, R., Jones, K., Krishnamurthi, R., & Feigin, V. (2014) · Neuroepidemiology · doi:10.1159/000369343 · Cited by 2,046
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70272-8 · Cited by 1,172
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., & Bushby, K. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00140-2 · Cited by 1,009
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Self-citationLocal Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Self-citationRecombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease
Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000251268.41188.04 · Cited by 781
Pulmonary Function Testing in Children. Techniques and Standards
(1973) · Clinical Pediatrics · doi:10.1177/000992287301200517 · Cited by 761
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Self-citationKinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70211-x · Cited by 653
Predicted normal values for maximal respiratory pressures in caucasian adults and children.
Wilson, S. H., Cooke, N. T., Edwards, R. H., & Spiro, S. G. (1984) · Thorax · doi:10.1136/thx.39.7.535 · Cited by 516
The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy
McDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Elfring, G. L., Atkinson, L., Reha, A., Hirawat, S., & Miller, L. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21544 · Cited by 397
McDonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J., Eagle, M., Gappmaier, E., Glanzman, A. M., PTC124‐GD‐007‐DMD Study Group, Spiegel, R., Barth, J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23905 · Cited by 354
Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy
Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R., Florence, J., King, W. M., Pandya, S., Robison, J., Schierbecker, J., et al. (1989) · Neurology · doi:10.1212/wnl.39.4.475 · Cited by 353
Self-citationVoit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S. J., Eagle, M., Guglieri, M., Hood, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70195-4 · Cited by 306
Mcdonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J. M., Eagle, M., Gappmaier, E., Glanzman, A. M., PTC124‐GD‐007‐DMD Study Group, Spiegel, R., Barth, J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23902 · Cited by 303
Ciafaloni, E., Fox, D. J., Pandya, S., Westfield, C. P., Puzhankara, S., Romitti, P. A., Mathews, K. D., Miller, T. M., Matthews, D. J., Miller, L. A., et al. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.02.007 · Cited by 245
Mazzone, E., Martinelli, D., Berardinelli, A., Messina, S., D’Amico, A., Vasco, G., Main, M., Doglio, L., Politano, L., Cavallaro, F., et al. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.06.014 · Cited by 216
Self-citationHenricson, E. K., Abresch, R. T., Cnaan, A., Hu, F., Duong, T., Arrieta, A., Han, J., Escolar, D. M., Florence, J. M., Clemens, P. R., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23808 · Cited by 208
Exon skipping therapy for Duchenne muscular dystrophy
Kole, R., & Krieg, A. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.008 · Cited by 192
McDonald, C. M., Henricson, E. K., Abresch, R. T., Han, J. J., Escolar, D. M., Florence, J. M., Duong, T., Arrieta, A., Clemens, P. R., Hoffman, E. P., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23807 · Cited by 183
Functional changes in Duchenne muscular dystrophy: A 12-month longitudinal cohort study
Mazzone, E., Vasco, G., Sormani, M. P., Torrente, Y., Berardinelli, A., Messina, S., D'Amico, A., Doglio, L., Politano, L., Cavallaro, F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab2e · Cited by 177
Self-citationThe 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations
MCDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Atkinson, L., Elfring, G. L., Reha, A., & Miller, L. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21808 · Cited by 172
Targeting RNA to treat neuromuscular disease
Muntoni, F., & Wood, M. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3459 · Cited by 171
Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes
Pane, M., Mazzone, E. S., Sivo, S., Sormani, M. P., Messina, S., D’Amico, A., Carlesi, A., Vita, G. L., Fanelli, L., Berardinelli, A. L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108205 · Cited by 157
Self-citationCharacterization of pulmonary function in Duchenne Muscular Dystrophy
Mayer, O. H., Finkel, R. S., Rummey, C., Benton, M. J., Glanzman, A. M., Flickinger, J., Lindström, B. ‐., & Meier, T. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23172 · Cited by 153
Henricson, E., Abresch, R. T., Han, J. J., Nicorici, A., Keller, E. G., de Bie, E., & McDonald, C. M. (2013) · PLoS Currents · doi:10.1371/currents.md.9e17658b007eb79fcd6f723089f79e06 · Cited by 137
Respiratory muscle decline in duchenne muscular dystrophy
Khirani, S., Ramirez, A., Aubertin, G., Boulé, M., Chemouny, C., Forin, V., & Fauroux, B. (2013) · Pediatric Pulmonology · doi:10.1002/ppul.22847 · Cited by 130
24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
Mazzone, E. S., Pane, M., Sormani, M. P., Scalise, R., Berardinelli, A. L., Messina, S., Torrente, Y., D’Amico, A., Doglio, L., Viggiano, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052512 · Cited by 128
Self-citationÇirak, S., Feng, L., Anthony, K., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.248 · Cited by 107
6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes
Pane, M., Mazzone, E. S., Sormani, M. P., Messina, S., Vita, G. L., Fanelli, L., Berardinelli, A. L., Torrente, Y., D’Amico, A., Lanzillotta, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083400 · Cited by 98
Self-citationSix-Minute Walk Test: Reference Values and Prediction Equation in Healthy Boys Aged 5 to12 Years
Goemans, N., Klingels, K., van den Hauwe, M., Boons, S., Verstraete, L., Peeters, C., Feys, H., & Buyse, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084120 · Cited by 69
Self-citationAVI-7288 for Marburg Virus in Nonhuman Primates and Humans
Heald, A. E., Charleston, J. S., Iversen, P. L., Warren, T. K., Saoud, J. B., Al-Ibrahim, M. S., Wells, J., Warfield, K. L., Swenson, D. L., Welch, L. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410345 · Cited by 63
Self-citationSafety Pharmacology and Genotoxicity Evaluation of AVI-4658
Sazani, P., Weller, D. L., & Shrewsbury, S. B. (2010) · International Journal of Toxicology · doi:10.1177/1091581809359206 · Cited by 44
Cited by
Birnkrant, D. J., Bushby, K., Bann, C. M., Apkon, S. D., Blackwell, A., Brumbaugh, D., Case, L. E., Clemens, P. R., Hadjiyannakis, S., Pandya, S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30024-3 · Cited by 1,370
Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,312
Self-citationNon-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Metadata
- Authors
- Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2016-01-08
- Volume
- 79
- Issue
- 2
- Pages
- 257-271
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2234725241
- Cited by
- 518
- References
- 36
- FWCI
- 20.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.